| 1 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 2 |
van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 5 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 7 |
Wang CH, Chang KK, Lin RC, Kuo MJ, Yang CC, Tseng YT. Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. Medicine (Baltimore) 2020;99:e19907. [PMID: 32358357 DOI: 10.1097/MD.0000000000019907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 8 |
Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 9 |
Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis 2018;19:561-71. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 10 |
Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 11 |
Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 12 |
Marciano S, Gadano A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int 2018;38 Suppl 1:97-101. [PMID: 29427480 DOI: 10.1111/liv.13627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 13 |
van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 14 |
Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 15 |
Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. Korean J Gastroenterol. 2016;67:28-34. [PMID: 26809629 DOI: 10.4166/kjg.2016.67.1.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 17 |
Kang SH, Kang K, Jong Eun Y, Lee YS, Kim TS, Yoo YJ, Suh SJ, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Byun KS. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. J Med Virol 2017;89:849-56. [PMID: 27769101 DOI: 10.1002/jmv.24715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 18 |
Horta D, Fernandez-atutxa A, Miquel M, Vergara M, Casas M, Sánchez-delgado J. Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir. Infectio 2016;20:123-129. [DOI: 10.1016/j.infect.2015.06.001] [Reference Citation Analysis]
|
| 19 |
Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016;63:1481-92. [PMID: 27100145 DOI: 10.1002/hep.28438] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 20 |
Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol 2016;16:38. [PMID: 26987437 DOI: 10.1186/s12876-016-0454-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 21 |
Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 22 |
Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 23 |
Lu J, Li J, Liu Y, Ren S, Cao Z, Jin Y, Ma L, Shen C, Chen X. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS One 2015;10:e0141072. [PMID: 26524467 DOI: 10.1371/journal.pone.0141072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 24 |
Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A, LeDuc VH, Nguyen N, Han SB, Chang M, Bae HS, Cho YW, Tong MJ, Cooper SL. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci 2015;60:3465-72. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 25 |
Siakavellas SI, Papatheodoridis GV. Controversial Issues in Current Treatment of Chronic HBV Infection. Curr Hepatology Rep 2015;14:164-170. [DOI: 10.1007/s11901-015-0268-4] [Reference Citation Analysis]
|
| 26 |
Jiang JN, Huang ZL, He LX, Huang YH, Su MH, Xie R, Liang YX, Fu WD, Huang XH, Guo WW, Zhong SH, Liu ZH, Li SH, Zhu TF, Gao ZL. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol 2015;49:323-8. [PMID: 25014234 DOI: 10.1097/MCG.0000000000000170] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 27 |
Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 28 |
Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 29 |
Martín-mateos RM, Moreira Vicente VF, Téllez-villajos L, García-sánchez C, Maroto-castellanos MT, García-alonso FJ, Mateos-lindemann ML, Albillos A. Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica. Gastroenterología y Hepatología 2014;37:280-8. [DOI: 10.1016/j.gastrohep.2013.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 30 |
He D, Guo S, Zhu P, Tao S, Li M, Huang H, Wang J, Wang Y, Ding M. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect. 2014;20:O687-O693. [PMID: 25469947 DOI: 10.1111/1469-0691.12605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 31 |
Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, Zhu R, Gao Z. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014;59:50-4. [DOI: 10.1016/j.jcv.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 32 |
Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, Yoon SK. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol. 2013;85:34-42. [PMID: 23154874 DOI: 10.1002/jmv.23421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 33 |
Ma H, Jia J. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue. Liver Int 2013;33 Suppl 1:133-6. [PMID: 23286857 DOI: 10.1111/liv.12065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Kim HY, Choi JY, Park CH, Jang JW, Kim CW, Bae SH, Yoon SK, Yang JM, Lee CD, Lee YS. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus. J Clin Virol 2013;56:299-305. [PMID: 23273664 DOI: 10.1016/j.jcv.2012.11.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 35 |
Tran TT. High frequency of viremia after hepatitis B e antigen seroconversion and consolidation therapy: setting realistic expectations. J Clin Gastroenterol 2012;46:807-8. [PMID: 23060214 DOI: 10.1097/MCG.0b013e31826b3030] [Reference Citation Analysis]
|
| 36 |
Ha M, Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol. 2012;157:285-290. [PMID: 22080196 DOI: 10.1007/s00705-011-1163-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 37 |
Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011;26:456-60. [PMID: 21332542 DOI: 10.1111/j.1440-1746.2010.06492.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 38 |
Fung J, Lai CL, Yuen MF. To stop or not to stop: the quest for long-term viral suppression. J Gastroenterol Hepatol 2011;26:420-2. [PMID: 21332537 DOI: 10.1111/j.1440-1746.2011.06604.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
